Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols

Alexander Popov; Barbara Buldini; Paola De Lorenzo; Silvia Disarò; Tatiana Verzhbitskaya; Liudmila Movchan; Emanuela Giarin; Egor Shorikov; Annamaria Di Meglio; Grigory Tsaur; Rosanna Parasole; Natalia Miakova; Elmira Boichenko; Konstantin Kondratchik; Olga Aleinikova; Alexander Karachunskiy; Alexander Roumiantsev; Franco Locatelli; Andrea Biondi; Rob Pieters; Maria Grazia Valsecchi; Larisa Fechina; Giuseppe Basso

doi:10.1038/s41375-020-0912-z

Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols

Leukemia. 2020 Nov;34(11):3042-3046. doi: 10.1038/s41375-020-0912-z. Epub 2020 Jun 12.

Authors

Alexander Popov^#¹, Barbara Buldini^#², Paola De Lorenzo^{3

4}, Silvia Disarò⁵, Tatiana Verzhbitskaya^{6

7}, Liudmila Movchan⁸, Emanuela Giarin⁵, Egor Shorikov⁹, Annamaria Di Meglio⁵, Grigory Tsaur^{6

7}, Rosanna Parasole¹⁰, Natalia Miakova¹¹, Elmira Boichenko¹², Konstantin Kondratchik¹³, Olga Aleinikova⁸, Alexander Karachunskiy¹¹, Alexander Roumiantsev¹¹, Franco Locatelli^{14

15}, Andrea Biondi⁴, Rob Pieters¹⁶, Maria Grazia Valsecchi³, Larisa Fechina^{6

7}, Giuseppe Basso^{2

17}

Affiliations

¹ National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation. uralcytometry@gmail.com.
² Dipartimento di Salute della Donna e del Bambino, University of Padua, Padua, Italy.
³ Interfant Trial Data Center, School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
⁴ Tettamanti Research Center, Pediatric Clinic, University of Milan-Bicocca, Fondazione MBBM/ S. Gerardo Hospital Monza, Monza, Italy.
⁵ Fondazione Città della Speranza - Onlus, Dipartimento di Salute della Donna e del Bambino, University of Padova, Padova, Italy.
⁶ Regional Children Hospital, Ekaterinburg, Russian Federation.
⁷ Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation.
⁸ Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.
⁹ PET-Technology Center of Nuclear Medicine, Ekaterinburg, Russian Federation.
¹⁰ Department of Pediatric Hemato-Oncology, Santobono-Pausilipon Hospital, Naples, Italy.
¹¹ National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
¹² City Children's Hospital №1, Saint-Petersburg, Russian Federation.
¹³ Morozov Children's Hospital, Moscow, Russian Federation.
¹⁴ Department of Pediatric Hematology and Oncology, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
¹⁵ Sapienza, University of Rome, Rome, Italy.
¹⁶ Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
¹⁷ Italian Institute for Genomic Medicine, Turin, Italy.

^# Contributed equally.

PMID: 32533093
DOI: 10.1038/s41375-020-0912-z

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Marrow / pathology
Female
Flow Cytometry* / methods
Humans
Incidence
Infant
Male
Neoplasm, Residual / diagnosis*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
Prognosis
Recurrence
Survival Analysis
Treatment Outcome